Neuraxpharm signs strategic license agreement with Minoryx for new therapy for rare CNS disease
Neuraxpharm firma un acuerdo de licencia estratégica con Minoryx para una nueva terapia para enfermedades raras del SNC
Intel ID : 356686
|
||||
| Intel ID | 356686 | |||
| Value | EUR 258,00m | |||
| Native Currency | Euro (EUR) | |||
|
Financial Data - Neuraxpharm
(31 Dec 2021) |
Revenue: EUR 56,11m EBITDA: EUR 11,76m Net Debt: EUR 53,05m People: 86 |
|||
| Date |
 |
|||
| Country |  |
|||
| Geography | |
|||
| Subsector (Old TTR Sectors) |
|
|||
| Primary Subsector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.03.06 Healthcare Research & Epidemiology (Primary) 30 Healthcare / 30.03 Healthcare Facilities & Services |
|||
| Secondary Subsectors (TTRSC) |
30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|||
| Type |
|
|||
| Intel Grade |
|
|||
| Source |
|
|||
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.03.06 Healthcare Research & Epidemiology 30 Healthcare / 30.03 Healthcare Facilities & Services |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Private Equity (Buyer)
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.09 Private Equity 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legal Advisory
| Parties | Advisor | Type | Notes from Advisors | |||||
|---|---|---|---|---|---|---|---|---|
|
-
- |
- | - | |||||
-
|
- | - |
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.